Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Meili is active.

Publication


Featured researches published by David Meili.


Human Mutation | 2009

Disease-causing mutations improving the branch site and polypyrimidine tract: pseudoexon activation of LINE-2 and antisense Alu lacking the poly(T)-tail

David Meili; Jana Kralovicova; Julian Zagalak; Luisa Bonafé; Laura Fiori; Nenad Blau; Beat Thöny; Igor Vorechovsky

Cryptic exons or pseudoexons are typically activated by point mutations that create GT or AG dinucleotides of new 5′ or 3′ splice sites in introns, often in repetitive elements. Here we describe two cases of tetrahydrobiopterin deficiency caused by mutations improving the branch point sequence and polypyrimidine tracts of repeat‐containing pseudoexons in the PTS gene. In the first case, we demonstrate a novel pathway of antisense Alu exonization, resulting from an intronic deletion that removed the poly(T)‐tail of antisense AluSq. The deletion brought a favorable branch point sequence within proximity of the pseudoexon 3′ splice site and removed an upstream AG dinucleotide required for the 3′ splice site repression on normal alleles. New Alu exons can thus arise in the absence of poly(T)‐tails that facilitated inclusion of most transposed elements in mRNAs by serving as polypyrimidine tracts, highlighting extraordinary flexibility of Alu repeats in shaping intron–exon structure. In the other case, a PTS pseudoexon was activated by an A>T substitution 9 nt upstream of its 3′ splice site in a LINE‐2 sequence, providing the first example of a disease‐causing exonization of the most ancient interspersed repeat. These observations expand the spectrum of mutational mechanisms that introduce repetitive sequences in mature transcripts and illustrate the importance of intronic mutations in alternative splicing and phenotypic variability of hereditary disorders. Hum Mutat 30, 1–9, 2009.


American Journal of Human Genetics | 2017

Biallelic Mutations in DNAJC12 Cause Hyperphenylalaninemia, Dystonia, and Intellectual Disability

Yair Anikster; Tobias B. Haack; Thierry Vilboux; Ben Pode-Shakked; Beat Thöny; Nan Shen; Virginia Guarani; Thomas Meissner; Ertan Mayatepek; Friedrich K. Trefz; Dina Marek-Yagel; Aurora Martinez; Edward L. Huttlin; Joao A. Paulo; Riccardo Berutti; Jean-François Benoist; Apolline Imbard; Imen Dorboz; Gali Heimer; Yuval E. Landau; Limor Ziv-Strasser; May Christine V. Malicdan; Corinne Gemperle-Britschgi; Kirsten Cremer; Hartmut Engels; David Meili; Irene Keller; Rémy Bruggmann; Tim M. Strom; Thomas Meitinger

Phenylketonuria (PKU, phenylalanine hydroxylase deficiency), an inborn error of metabolism, can be detected through newborn screening for hyperphenylalaninemia (HPA). Most individuals with HPA harbor mutations in the gene encoding phenylalanine hydroxylase (PAH), and a small proportion (2%) exhibit tetrahydrobiopterin (BH4) deficiency with additional neurotransmitter (dopamine and serotonin) deficiency. Here we report six individuals from four unrelated families with HPA who exhibited progressive neurodevelopmental delay, dystonia, and a unique profile of neurotransmitter deficiencies without mutations in PAH or BH4 metabolism disorder-related genes. In these six affected individuals, whole-exome sequencing (WES) identified biallelic mutations in DNAJC12, which encodes a heat shock co-chaperone family member that interacts with phenylalanine, tyrosine, and tryptophan hydroxylases catalyzing the BH4-activated conversion of phenylalanine into tyrosine, tyrosine into L-dopa (the precursor of dopamine), and tryptophan into 5-hydroxytryptophan (the precursor of serotonin), respectively. DNAJC12 was undetectable in fibroblasts from the individuals with null mutations. PAH enzyme activity was reduced in the presence of DNAJC12 mutations. Early treatment with BH4 and/or neurotransmitter precursors had dramatic beneficial effects and resulted in the prevention of neurodevelopmental delay in the one individual treated before symptom onset. Thus, DNAJC12 deficiency is a preventable and treatable cause of intellectual disability that should be considered in the early differential diagnosis when screening results are positive for HPA. Sequencing of DNAJC12 may resolve any uncertainty and should be considered in all children with unresolved HPA.


Molecular Genetics and Metabolism | 2011

Autism associated with low 5-hydroxyindolacetic acid in CSF and the heterozygous SLC6A4 gene Gly56Ala plus 5-HTTLPR L/L promoter variants

Dea Adamsen; David Meili; Nenad Blau; Beat Thöny; Vincent Ramaekers

The known Gly56Ala mutation in the serotonin transporter SERT (or 5-HTT), encoded by the SLC6A4 gene, causes increased serotonin reuptake and has been associated with autism and rigid-compulsive behavior. We report a patient with macrocephaly from birth, followed by hypotonia, developmental delay, ataxia and a diagnosis of atypical autism (PDD-NOS) in retrospect at the age of 4½years. Low levels of the serotonin end-metabolite 5-hydroxyindolacetic acid (5HIAA) in CSF were detected, and SLC6A4 gene analysis revealed the heterozygous Gly56Ala alteration and the homozygous 5-HTTLPR L/L promoter variant. These changes are reported to be responsible for elevated SERT activity and expression, suggesting that these alterations were responsible in our patient for low serotonin turnover in the central nervous system (CNS). Daily treatment with 5-hydroxytryptophan (and carbidopa) led to clinical improvement and normalization of 5HIAA, implying that brain serotonin turnover normalized. We speculate that the mutated 56Ala SERT transporter with elevated expression and basal activity for serotonin re-uptake is accompanied with serotonin accumulation within pre-synaptic axons and their vesicles in the CNS, resulting in a steady-state of lowered serotonin turnover and degradation by monoamine-oxidase (MAO) enzymes in pre-synaptic or neighboring cells.


Journal of Biology | 2006

The Short Coiled-Coil Domain-Containing Protein UNC-69 Cooperates with UNC-76 to Regulate Axonal Outgrowth and Normal Presynaptic Organization in Caenorhabditis elegans

Cheng-Wen Su; Suzanne Tharin; Yishi Jin; Bruce Wightman; Mona S. Spector; David Meili; Nancy Tsung; Christa Rhiner; Dimitris Bourikas; Esther T. Stoeckli; Gian Garriga; H. Robert Horvitz; Michael O. Hengartner

Background The nematode Caenorhabditis elegans has been used extensively to identify the genetic requirements for proper nervous system development and function. Key to this process is the direction of vesicles to the growing axons and dendrites, which is required for growth-cone extension and synapse formation in the developing neurons. The contribution and mechanism of membrane traffic in neuronal development are not fully understood, however. Results We show that the C. elegans gene unc-69 is required for axon outgrowth, guidance, fasciculation and normal presynaptic organization. We identify UNC-69 as an evolutionarily conserved 108-amino-acid protein with a short coiled-coil domain. UNC-69 interacts physically with UNC-76, mutations in which produce similar defects to loss of unc-69 function. In addition, a weak reduction-of-function allele, unc-69(ju69), preferentially causes mislocalization of the synaptic vesicle marker synaptobrevin. UNC-69 and UNC-76 colocalize as puncta in neuronal processes and cooperate to regulate axon extension and synapse formation. The chicken UNC-69 homolog is highly expressed in the developing central nervous system, and its inactivation by RNA interference leads to axon guidance defects. Conclusion We have identified a novel protein complex, composed of UNC-69 and UNC-76, which promotes axonal growth and normal presynaptic organization in C. elegans. As both proteins are conserved through evolution, we suggest that the mammalian homologs of UNC-69 and UNC-76 (SCOCO and FEZ, respectively) may function similarly.


Molecular Genetics and Metabolism | 2005

Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: A pilot study

Betina Fiege; Luisa Bonafé; Diana Ballhausen; Matthias R. Baumgartner; Beat Thöny; David Meili; Laura Fiori; Marcello Giovannini; Nenad Blau


Molecular Autism | 2014

Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene

Dea Adamsen; Vincent Ramaekers; Horace T. B. Ho; Corinne Britschgi; Véronique Rüfenacht; David Meili; Elise Bobrowski; Paule Philippe; Caroline Nava; Lionel Van Maldergem; Rémy Bruggmann; Susanne Walitza; Joanne Wang; Edna Grünblatt; Beat Thöny


Human Mutation | 2011

Pseudoexon exclusion by antisense therapy in 6‐pyruvoyl‐tetrahydropterin synthase deficiency

Sandra Brasil; Hiu Man Viecelli; David Meili; Anahita Rassi; Lourdes R. Desviat; Belén Pérez; Magdalena Ugarte; Beat Thöny


JIMD Reports | 2015

Heterozygous Monocarboxylate Transporter 1 (MCT1, SLC16A1) Deficiency as a Cause of Recurrent Ketoacidosis

Shanti Balasubramaniam; Barry Lewis; Lawrence Greed; David Meili; Annegret Flier; Raina Yamamoto; Karmen Bilić; Claudia Till; Jörn Oliver Sass


International Congress on Inborn Errors of Metabolism (11 ; 2009) | 2009

Genotype-based prediction of BH4-responsiveness in PKU patients

Caroline Heintz; Iva Karačić; David Meili; Vladimir Sarnavka; Thony; Danijela Petković Ramadža; Ksenija Fumić; Duško Mardešić; Ivo Barić; Nenad Blau


International Congress of Inborn Errors of Metabolism (11 ; 2009) | 2009

Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency

Iva Karačić; David Meili; Vladimir Sarnavka; Caroline Heintz; Beat Thöny; Danijela Petković Ramadža; Ksenija Fumić; Duško Mardešić; Ivo Barić; Nenad Blau

Collaboration


Dive into the David Meili's collaboration.

Top Co-Authors

Avatar

Beat Thöny

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Nenad Blau

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Caroline Heintz

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

H. Robert Horvitz

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Mona S. Spector

Cold Spring Harbor Laboratory

View shared research outputs
Top Co-Authors

Avatar

Nancy Tsung

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge